This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sinzinger, H. Articles by Peskar, B. A. Search for Related Content PubMed PubMed Citation Articles by Sinzinger, H. Articles by Peskar, B. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Platelet Half-Life, Plasma Thromboxane B2 and Circulating Endothelial-Cells in Peripheral Vascular Disease

Peter Fitscha

Bernhard A. Peskar

We studied platelet half-life (T/2), plasma thromboxane B₂-levels (TXB₂) and circulating endothelial cells in 107 patients with a mean age of 63 ± 6.8 years and angiographically proven peripheral vascular disease (PVD). Patients were divided into 4 groups according to Fontaine but also according to additional clinical manifestations of atherosclerosis like coronary heart disease (CHD) and cerebrovascular disease (CVD). Furthermore, the influence of sex and smoking was investigated.

Compared to patients without atherosclerotic manifestations we could detect an enhanced platelet consumption measured as shortended platelet half-life time (79.2 ± 9.1 vs 100.9 ± 5.6 hours, p < 0.001 and an increased platelet activity measured as increased TXB₂-plasma levels (51.6 ± 20.9 vs 23.2 ± 11.2 ng/ml, p < 0.001). Correspondingly, the amount of circulating endothelial cells was increased 45.2 ± 25.7 vs 20.3 ± 23.4, p < 0.001). Patients with PVD who smoked had the shortest actual platelet half-life, the highest TXB₂ plasma levels and the greatest amount of circulating endothelial cells compared to non-smok ing patients and controls.

Patients with clinical stage IV according to Fontaine had the shortest platelet half-life, the highest TXB₂ plasma levels and the greatest amount of circulating endothelial cells compared to the other clinical stages. Analyzing the influence of additional clinical manifestations of atherosclerosis we could detect only in patients with PVD and CHD significant differences compared to the other groups.

Angiology, Vol. 37, No. 2, 112-118 (1986)
DOI: 10.1177/000331978603700207


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. Coto, M. Cocozza, U. Oliviero, A. Lucariello, T. Picano, F. Coto, and L. Cacciatore Clinical Efficacy of Picotamide in Long-Term Treatment of Intermittent Claudication Angiology, October 1, 1989; 40(10): 880 - 885. [Abstract] [PDF]

				R. Testa, A. Biagini, C. Michelassi, M. Emdin, M. G. Mazzei, C. Carpeggiani, and A. l'Abbate Improvement of Walking Distance in Patients with Intermittent Claudication by Chronic Local Therapy with Isosorbide Dinitrate Ointment Angiology, January 1, 1988; 39(1): 1 - 7. [Abstract] [PDF]

				J.C. Arcan, J. Blanchard, J.P. Boissel, J.M. Destors, and E. Panak Multicenter Double-Blind Study of Ticlopidine in the Treatment of Intermittent Claudication and the Prevention of its Complications Angiology, January 1, 1988; 39(9): 802 - 811. [Abstract] [PDF]